Your browser doesn't support javascript.
loading
Drug-Drug Interactions in Elderly Patients with Potentially Inappropriate Medications in Primary Care, Nursing Home and Hospital Settings: A Systematic Review and a Preliminary Study.
Bories, Mathilde; Bouzillé, Guillaume; Cuggia, Marc; Le Corre, Pascal.
Afiliação
  • Bories M; Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, CHU de Rennes, 35033 Rennes, France.
  • Bouzillé G; Univ Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, F-35000 Rennes, France.
  • Cuggia M; Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, 35043 Rennes, France.
  • Le Corre P; Univ Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, F-35000 Rennes, France.
Pharmaceutics ; 13(2)2021 Feb 16.
Article em En | MEDLINE | ID: mdl-33669162
ABSTRACT
Drug-drug interactions (DDI) occurring with potentially inappropriate medications (PIM) are additional risk factors that may increase the inappropriate character of PIM. The aim of this study was (1) to describe the prevalence and severity of DDI in patients with PIM and (2) to evaluate the DDI specifically regarding PIM. This systematic review is based on a search carried out on PubMed and Web-of-Science from inception to June 30, 2020. We extracted data of original studies that assessed the prevalence of both DDI and PIM in elderly patients in primary care, nursing home and hospital settings. Four hundred and forty unique studies were identified 91 were included in the qualitative analysis and 66 were included in the quantitative analysis. The prevalence of PIM in primary care, nursing home and hospital were 19.1% (95% confidence intervals (CI) 15.1-23.0%), 29.7% (95% CI 27.8-31.6%) and 44.6% (95% CI 28.3-60.9%), respectively. Clinically significant severe risk-rated DDI averaged 28.9% (95% CI 17.2-40.6), in a hospital setting; and were approximately 7-to-9 lower in primary care and nursing home, respectively. Surprisingly, only four of these studies investigated DDI involving specifically PIM. Hence, given the high prevalence of severe DDI in patients with PIM, further investigations should be carried out on DDI involving specifically PIM which may increase their inappropriate character, and the risk of adverse drug reactions.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Qualitative_research / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Pharmaceutics Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Qualitative_research / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Pharmaceutics Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França